Barcelona, September 24th of 2019. The 6-month results of TINTIN (Treatment with the lumINor DCB and The IVolutioN self-expanding stent) trial have been revealed at CIRSE 2019 by Dr. Koen Deloose.
TINTIN is a physician-initiated trial investigating the safety and efficacy of the treatment with the luminor DCB and iVolution self-expanding stent, in TASC C and D femoropopliteal lesions.
Both iVolution and luminor present excellent outcomes in TASC A & B lesions, but it is clear, out of the literature, that neither BMS nor DCB alone are winners in long, complex lesions and on the longer run. The combination of both is the key to success in these situations.
TINTIN trial outcomes:
Primary patency of 96.5%
Freedom from TLR of 98.9%
At the end of the presentation, Dr. Deloose concluded that:
“The Belgian TINTIN trial shows impressive 6 months results in lesions of 24 cm”.
About luminor DCB
luminor is a paclitaxel-coated balloon specifically designed for dilatation of stenosis located in the iliac, femoral, iliofemoral, popliteal, infrapopliteal and renal arteries, as well as for the treatment of obstructive lesions of arteriovenous fistulas, whether original or artificial. The balloon is coated with a homogeneous mixture of paclitaxel using iVascular proprietary technology TransferTech. This technology applies a multilayer of the drug by spraying nanodrop through ultrasound to have less drug loss during manipulation and navigation.
luminor: EFFPAC trial
About iVolution self-expanding stent
The peripheral self-expanding stent system iVolution, is indicated for the treatment of de novo or restenotic lesions in peripheral arteries located under the aortic arch and for palliation of the biliary tract. The outcomes of the EVOLUTION trial demonstrate that the outstanding flexibility and the high-quality nitinol of the stent make iVolution an effective alternative to treat femoropopliteal lesions.